Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.

摘要: Lung cancer is the leading cause of cancer-related death in United States. Here, we evaluated potential clinical utility soluble human epidermal growth factor receptor 2 (sHER2) for risk assessment, screening, and diagnosis non-small cell lung (NSCLC) using an unmatched case-control study design. Serum sHER2 concentrations were measured by immunoassay 244 primary NSCLC cases 218 healthy controls. Wilcoxon rank-sum tests, logistic regression models, receiver operating characteristic plots used to assess whether associated with cancer. Median serum are higher patients adenocarcinoma than squamous carcinoma regardless gender, a weak, independent biomarker adenocarcinoma, but not carcinoma, adjusted age gender. The age-adjusted relative (odds) 3.95 (95% CI: 1.22, 12.81) 7.93 2.26, 27.82) greater women men high (≥6.60 ng/mL) vs. low (≤1.85 ng/mL), respectively. When each other, sHER2, age, gender discern controls from adenocarcinomas 85.9% accuracy. We conclude that even though strong, stand-alone discriminatory may be useful, covariate multivariate diagnostic models